GlobalData on MSN22h
AbbVie enters obesity space with $2.3bn Gubra dealAbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...
Zacks.com on MSN21h
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin DrugAbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s ...
The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.
On World Obesity Day, the public health doctor says while much is changing around drugs and weight loss, we cannot lose sight ...
Teva Pharmaceutical Industries Ltd. ADR 0.86% $19.12B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback